From the diagnostic work-up, the APN and staff nurse understand that the having a clinical presentation of age greater than 1 year, and less than 9 years, having white count< 50,000/mm3, being hyperdiploid, and having no translocation in the leukemia blast would categorize this patient as having a favorable prognosis. Therefore, this patient would be entered on the low-risk-adapted treatment protocol. Although the patient has a favorable the outcome, it is imperative that the APN order the needed surveillance to assure appropriate response to therapy. The fist response bone marrow is obtained on Day 19 of induction. The family is aware of the importance of this bone marrow examination and understands that the results will affect therapy. While awaiting the bone marrow results, the nurse verifies that the family has an understanding of the procedure, and the nurse clarifies any questions to facilitate their understanding. If the molecular analysis is positive for>1% leukemia, the attending physician APN will discuss these finding with the family and patient, at which time the patient will undergo intensification of therapy and treatment protocol change. To standard risk. Day 19 bone marrow shows an excellent molecular response during induction without significant side effects and receives all scheduled therapy. At the end of the induction-remission therapy, the bone marrow examination is repeated, with no evidence of leukemia on morphological examination and a molecular analysis of